Gene Editing for Immuno Oncology

Power Your Immune-Oncology Projects with Custom Engineered Immune Cells

Gene-editing in immune cell lines can be challenging due to low targeting efficiency and difficulties in single cell derivation of suspension cells. Horizon has validated 10+ immune cell lines including THP-1, Jurkat and NALM-6 cells for gene-editing projects. CRISPR, rAAV and ZFN gene-editing technologies are available depending on project requirements.

Take advantage of the largest panel of pre-characterized immune cell lines available and benefit from Horizon’s exceptional knowhow and experience in completing over 2,000 gene-editing projects.

Request more infocontact usrmation

Gene-Editing for Immuno-Oncology Offering

  • Modifications: Knockin, knockout (point mutations, tags and reporter genes)
  • Technologies: CRISPR, rAAV or ZFN depending on project requirements
  • Project types: Standard or Premium 
  • Estimated timeline: 13-32 weeks
  • Deliverables: Isogenic cell line pair and a summary report

Cell Lines Including

Cell line

Species

Cell Type

Disease

TF-1

Human

Erythroblast

Erythroleukemia

THP-1

Human

Monocyte

Acute monocytic leukemia

MOLT-4

Human

T-lymphoblast

Acute lymphoblastic leukemia

NALM-6

Human

B-cell

Acute lymphoblastic leukemia

KMS-11

Human

B-cell precursor

Myeloma

K-562

Human

Lymphoblast

Chronic myelogenous leukemia

Jurkat

Human

T-lymphocyte

Acute T-cell leukemia

J.RT3-T3.5

Human

T-lymphocyte

Acute T-cell leukemia

H9

Human

Cutaneous T-lymphocyte

Lymphoma

CCRF-CEM

Human

T-lymphoblast

Acute lymphoblastic leukemia

A20

Mouse

B-lymphocyte

Reticulum cell sarcoma

Case Study I: Heterozygous CRISPR Knockout in Jurkat Cells

Case Study 1 Diagram

Positive clone with heterozygous knockout was identified by PCR and Sanger sequencing. An 11 bp deletion introducing a premature stop codon at position 51 exists in one allele.

Case Study II: CRISPR-Mediated Gene Disruption in THP-1 Cells

Case Study 2 Diagram

Following transfection of THP-1 cells with CRISPR targeting reagents directed against two genes, CRISPR mediated disruption of each gene was identified (indicated by *) by Surveyor assay.

Learn more about our HTS immuno-oncology assays